Search results for "triazol"
showing 10 items of 598 documents
X-Ray structure, Hirshfeld analysis and DFT studies of two new hits of triazolyl-indole bearing alkylsulfanyl moieties
2021
Two new hits of triazolyl-indole containing two different alkylsulfanyl analogues named tert-butyl 2-((4-amino-5-(1H-indol-2-yl)-4H-1,2,4-triazol-3-yl)thio)acetate 2, and ethyl 2-((4-amino-5-(1H-indol-2-yl)-4H-1,2,4-triazol-3-yl)thio)acetate 3 were synthesized via reaction of 4-amino-5-(1H-indol-2-yl)-1,2,4-triazol-3(2H)-thione 1 with tert-butyl bromoacetate and ethyl chloroacetate in the presence of base (Et3N). The molecular structure of 2, and 3 was confirmed by single-crystal X-ray diffraction and 1H/13C- NMR spectroscopic techniques. In compound 2, the molecular packing depends on significant O...H (9.3%), N...H (12.4%) and S...H (3.1%) as well as relatively weak C...H (14.1%), S...C (…
Bioactive compounds containing benzoxadiazole, benzothiadiazole, benzotriazole.
2010
[3+2]‐Cycloadditions of N ‐Cyano Sulfoximines with 1,3‐Dipoles
2020
Involving the cyano group of N‐cyano sulfoximines in [3+2]‐cycloaddition reactions with 1,3‐dipoles provides practical routes for the construction of 5‐membered heterocycles bearing sulfoximinoyl moieties. An ytterbium‐catalyzed cycloaddition utilizing hydrazonoyl chlorides was developed, as well as a reaction involving imidoyl chlorides proceeding without the aid of a catalyst. Following these protocols, a range of sulfoximines with N‐1,2,4‐triazolyl and N‐1,2,4‐oxadiazolyl substituents was prepared. peerReviewed
CCDC 1417554: Experimental Crystal Structure Determination
2015
Related Article: Tania Romero-Morcillo, Francisco Javier Valverde-Muñoz, Lucía Piñeiro-López, M. Carmen Muñoz, Tomás Romero, Pedro Molina, José A. Real|2015|Dalton Trans.|44|18911|doi:10.1039/C5DT03084F
CCDC 736124: Experimental Crystal Structure Determination
2010
Related Article: R.Ballesteros-Garrido, B.Abarca, R.Ballesteros, C.R.de Arellano, F.R.Leroux, F.Colobert, E.Garcia-Espana|2009|New J.Chem.|33|2102|doi:10.1039/b906992e
CCDC 915014: Experimental Crystal Structure Determination
2013
Related Article: Zulema Arcis-Castillo,Lucia Pineiro-Lopez,M. Carmen Munoz,Rafael Ballesteros,Belen Abarca,Jose Antonio Real|2013|CrystEngComm|15|3455|doi:10.1039/C3CE00003F
CCDC 293619: Experimental Crystal Structure Determination
2007
Related Article: E.Aznar, S.Ferrer, J.Borras, F.Lloret, M.Liu-Gonzalez, H.Rodriguez-Prieto, S.Garcia-Granda|2006|Eur.J.Inorg.Chem.||5115|doi:10.1002/ejic.200600711
Derivados de [1,2,3]triazolo[1,5-a]quinolina y [1,2,3]triazolo[1,5-a]piridina. Interacción con adn. Actividad fotonucleasa. Potenciales aplicaciones …
2018
La tesis que se presenta lleva por título: “Derivados de [1,2,3]triazolo[1,5a]quinolina y [1,2,3]triazolo[1,5-a] piridina. Interacción con ADN. Actividad fotonucleasa. Potenciales aplicaciones como anti-tumorales o agentes leishmanicidas”. Se ha sintetizado una serie de compuestos monocatiónicos y dicatiónicos derivados de la [1,2,3]triazolo[1,5-a]quinolina, obteniéndose monosales y disales de triazoloquinolinio. Se ha estudiado la capacidad de estas sales de interaccionar con ADN, y de dar complejos de intercalación con él. Se han hecho estudios de desnaturalización térmica, UV-Visible, fluorescencia y viscosimetría. En general se ha observado interacción con el ADN pero con estos estudios…
Overcoming Imatinib resistance using CAI, a calcium-mediated signal transduction inhibitor: A new therapeutic strategy for chronic myelogenous leucem…
2008
carboxyamidotriazole-orotate inhibits the growth of imatinib resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis
2012
The Bcr/Abl kinase has been targeted for the treatment of chronic myelogenous leukaemia (CML) by imatinib mesylate. Although more common in solid tumors, increased microvessel density was also reported in chronic myelogenous leukaemia and was associated with a significant increase of angiogenic factors, suggesting that vascularity in haematologic malignancies is a controlled process and may play a role in the leukaemogenic process thus representing an alternative therapeutic target. Carboxyamidotriazole-orotate (CTO) is the orotate salt form of carboxyamidotriazole (CAI), an orally bioavailable signal transduction inhibitor that in vitro has been shown to possess antileukaemic activities (1…